Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Bristol-Myers Squibb (BMY)
Analysts fell to the sidelines weighing in on Arvinas Holding Company (ARVN – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Confident Investing Starts Here:
Arvinas Holding Company (ARVN)
Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Arvinas Holding Company yesterday. The company's shares closed last Friday at $7.20.
According to TipRanks.com, Biegler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $14.66 average price target, implying a 95.5% upside from current levels. In a report released yesterday, Leerink Partners also downgraded the stock to Hold with a $9.00 price target.
Bristol-Myers Squibb (BMY)
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb on May 31. The company's shares closed last Friday at $48.28.
According to TipRanks.com, Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Eli Lilly & Co.
The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $55.53 average price target, representing a 16.0% upside. In a report issued on May 16, BMO Capital also maintained a Hold rating on the stock with a $53.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Analysts Offer Insights on Technology Companies: Pure Storage (PSTG) and Xero Limited (OtherXROLF)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Pure Storage (PSTG – Research Report) and Xero Limited (XROLF – Research Report) with bullish sentiments. Confident Investing Starts Here: Pure Storage (PSTG) In a report released today, Jason Ader from William Blair reiterated a Buy rating on Pure Storage. The company's shares closed last Tuesday at $54.87. According to Ader is a 4-star analyst with an average return of 4.6% and a 55.3% success rate. Ader covers the Technology sector, focusing on stocks such as DigitalOcean Holdings, CommVault Systems, and Varonis Systems. Pure Storage has an analyst consensus of Strong Buy, with a price target consensus of $72.24, a 34.1% upside from current levels. In a report issued on May 23, Evercore ISI also maintained a Buy rating on the stock with a $70.00 price target. Xero Limited (XROLF) Jarden analyst Tom Beadle maintained a Buy rating on Xero Limited today and set a price target of A$197.00. The company's shares closed last Tuesday at $116.01, close to its 52-week high of $118.88. According to Beadle is a 2-star analyst with an average return of 0.0% and a 56.1% success rate. Beadle covers the NA sector, focusing on stocks such as Telstra Corporation Limited, TPG Telecom Limited, and REA Group Ltd. Currently, the analyst consensus on Xero Limited is a Strong Buy with an average price target of $132.45, a 14.2% upside from current levels. In a report issued on May 19, Citi also maintained a Buy rating on the stock with a A$210.00 price target.
Yahoo
2 hours ago
- Yahoo
Why BioNTech Stock Soared Today
BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase 3 trials, and now Bristol will help to fund further trials. Cash payments to BioNTech could exceed $11 billion over time. 10 stocks we like better than BioNTech Se › BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely unrelated to COVID. The German biotech announced this morning it is partnering with pharmaceuticals giant Bristol Myers Squibb (NYSE: BMY) to "co-develop and co-commercialize" BioNTech's drug candidate BNT327 as an immunotherapy against multiple kinds of cancer. BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is already involved in "multiple" ongoing clinical trials, including an advanced phase 3 trial testing its usefulness in treating breast cancer and both small cell and non-small cell lung cancer. BioNTech CEO Dr. Uğur Şahin expressed the belief that "BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications." Bristol CEO Christopher Boerner agreed that BNT327 has "significant potential for transforming the standard of care for patients with solid tumors." There are more immediate benefits for BioNTech stock, beginning with Bristol Myers Squibb paying BioNTech $1.5 billion up front for the rights to team up and a further $2 billion in noncontingent payments through 2028 as drug development continues. Additional developmental, regulatory, and commercial milestones, which are contingent on successful development, could add a further $7.6 billion to BioNTech's balance sheet over time. With its lucrative COVID days behind it, BioNTech reported nearly $690 million in losses last year and turned free-cash-flow negative. A tidal wave of cash from Bristol Myers Squibb could really come in handy right about now. Before you buy stock in BioNTech Se, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and BioNTech Se wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. Why BioNTech Stock Soared Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
21 hours ago
- Business Insider
Analysts Offer Insights on Technology Companies: Sensata (ST) and Develop Global Limited (OtherVTEXF)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Sensata (ST – Research Report) and Develop Global Limited (VTEXF – Research Report) with bullish sentiments. Confident Investing Starts Here: Sensata (ST) TD Cowen analyst Joseph C Giordano maintained a Buy rating on Sensata yesterday and set a price target of $45.00. The company's shares closed last Monday at $25.70, close to its 52-week low of $24.42. According to Giordano is a 5-star analyst with an average return of 7.7% and a 60.7% success rate. Giordano covers the Industrial Goods sector, focusing on stocks such as Watts Water Technologies, Veralto Corporation, and Rockwell Automation. Currently, the analyst consensus on Sensata is a Hold with an average price target of $28.30. Develop Global Limited (VTEXF) In a report issued on May 29, Tim McCormack from Canaccord Genuity maintained a Buy rating on Develop Global Limited, with a price target of A$5.05. The company's shares closed last Tuesday at $1.40. According to McCormack is a top 100 analyst with an average return of 22.7% and a 66.5% success rate. McCormack covers the Basic Materials sector, focusing on stocks such as Northern Star Resources Ltd, Ramelius Resources Limited, and Gascoyne Resources Limited. Currently, the analyst consensus on Develop Global Limited is a Moderate Buy with an average price target of $2.92.
